Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT, Fruquintinib, and Cadonilimab in 3L mCRC
NCT05747716Phase 2Not yet recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, fruquintinib in colorectal cancer (metastatic) (mCRC). Planned start Feb 2023; status: not yet recruiting.
02
Drugs
cadonilimabfruquintinib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05747716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747716.